News

Catalyst Pharmaceuticals Inc. stock rises Tuesday, still underperforms market
Catalyst Pharmaceuticals Inc. closed 13.60% below its 52-week high of $26.16, which the company reached on March 24th.
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
Catalyst Pharmaceuticals Inc. closed 15.82% short of its 52-week high of $26.16, which the company achieved on March 24th.
Catalyst Pharmaceuticals price target raised to $34 from $33 at BofA
BofA raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $34 from $33 and keeps a Buy rating on the shares. The firm, in its ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalyst Pharma (CPRX), Ascendis Pharma (ASND) and Avanos Medical (AVNS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Catalyst Pharma (CPRX – Research Report), ...
Catalyst Watch: Spotlight on Tesla, Alphabet earnings, AACR drug data, and global PMI reports
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more ...
Healthy Returns: What drugmakers are saying about Trump's looming pharmaceutical tariffs
What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its ...